Our collaborative nature ensures you have an individualized treatment ... can present as ILD too. For patients with connective tissue disorders (CTD) and ILDs (e.g., Rheumatoid arthritis, Scleroderma, ...

It is important that treatment decisions be individualized ... Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients.

This information could help your doctor choose the right treatment ... Just as dermatomyositis can affect the heart muscle, it can also affect lung tissue, causing interstitial lung disease.

He had no clinical, radiological, or laboratory evidence of myositis, interstitial lung disease, neuropathy ... A diagnosis of anti-MDA5 amyopathic dermatomyositis was made. Treatment with a ...

a treatment for pulmonary hypertension in patients with interstitial lung disease (PH-ILD), which was recently introduced. The meeting with Roivant Sciences' CEO, CFO, and Head of Investor ...

A summary of the clinical characteristics and treatment strategies of patients with anti-MDA5+DM with different HRCT patterns is provided in table 2. Patients with NSIP+OP pattern had a shorter time ...

VTAMA ® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque ...

The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. BASEL ... for pulmonary hypertension associated with interstitial lung ...

However, due to the toxicity associated with cyclophosphamide therapy, they did not want to use it as a first-line treatment. In conclusion, we reported a life-threatening case of dermatomyositis with ...